Salarius Pharmaceuticals, Inc. (SLRX)

Salarius Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	1	3	3	22	18	15
Market Cap Growth	-51.62%	-26.56%	-84.44%	24.07%	17.42%	157.99%
Enterprise Value	-3	-3	-9	-7	7	12
PE Ratio	-	-0.20	-0.11	-1.75	-2.33	-2.22
PS Ratio	-	-	-	12.18	3.45	4.44
PB Ratio	0.30	0.48	0.34	0.58	0.82	1.45
P/FCF Ratio	-0.21	-0.20	-0.20	-2.20	-1.75	-1.33
P/OCF Ratio	-0.21	-0.20	-0.20	-2.20	-1.75	-1.33
EV/Sales Ratio	-	-	-	-3.70	1.42	3.50
EV/EBITDA Ratio	0.22	0.24	0.27	0.53	-1.01	-1.78
EV/EBIT Ratio	0.22	0.24	0.27	0.53	-1.01	-1.75
EV/FCF Ratio	0.18	0.24	0.49	0.67	-0.72	-1.05
Debt / Equity Ratio	0.03	0.05	-	-	0.02	0.05
Debt / EBITDA Ratio	-0.01	-0.02	-	-	-0.07	-0.07
Debt / FCF Ratio	-0.01	-0.02	-	-	-0.05	-0.04
Quick Ratio	3.54	4.54	3.22	14.60	5.40	1.13
Current Ratio	3.91	5.02	3.40	14.29	5.70	1.42
Asset Turnover	0	0	0	0.04	0.24	0.32
Return on Equity (ROE)	-152.20%	-198.00%	-138.50%	-29.00%	-39.90%	-82.30%
Return on Assets (ROA)	-111.70%	-135.20%	-122.10%	-27.90%	-35.80%	-63.50%
Return on Capital (ROIC)	-245.48%	-231.22%	-306.62%	-33.09%	-34.40%	-74.57%
Earnings Yield	-816.14%	-489.95%	-906.79%	-56.99%	-42.91%	-45.10%
FCF Yield	-1009.57%	-501.81%	-504.79%	-45.53%	-57.12%	-75.30%
Buyback Yield / Dilution	-75.36%	-53.66%	-28.40%	-165.53%	-376.61%	-112.33%
Total Shareholder Return	-75.36%	-53.66%	-28.40%	-165.53%	-376.61%	-112.33%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).